Smith & Nephew PLC (SNN) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Smith & Nephew PLC (SNN)

28.81

-1.47 (4.85%)

as of Jun 30, 2026, 8:00:00 pm Market Open.

33 watching

Investor Insights

Jun 30, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Smith & Nephew PLC has undergone significant improvements under new management over the last four years, leading to enhanced revenue and profitability. The company's brand recognition has also increased, positioning it favorably in the orthopedic services market, which includes joint repairs and specialty dressings. Notably, analysts highlight that SNN-N is trading at approximately half the valuation of its largest competitor, Stryker, while exhibiting similar profitability margins. This attractive valuation combined with consistent margin improvements and industry growth forecasts indicates strong potential for market upside and opportunities for investors. As a result, the stock has been positively reviewed, with no sell ratings and a favorable analyst price target of $35.82, emphasizing its appeal for those seeking long-term investment growth.

Consensus

Buy

Valuation

Undervalued

Similar

SYK

COMMENT

Have turned the business around and are starting to grow. Not a lot of debt, ROC is more than 10%. Dividend not growing a lot. He owns Stryker instead. Middle of the road in its sector. Not a leader.

COMMENT

Has owned it in the past. Primary business in orthopedics. Great company. Last quarter has been mixed. There is speculation that they are buying Boston Scientific. Valuation wise it is OK. Stryker (SYK-N) is taking leadership in the orthopedic space. Longer term he prefers Stryker (SYK-N).

DON'T BUY

Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader.

PAST TOP PICK

(A Top Pick Aug 11/11. Up 24.13%.) Demand for discretionary medical devices has been affected by the economy. Like many European companies, the valuations are quite low and can have further upside from here.

PAST TOP PICK

(A Top Pick Feb 23/11. Down 10.95%.) Medical devices. Just reported strong numbers. Volumes in replacement knees has suffered because of the economy but still likes this long-term because of demographic tailwinds. Strong possibility it will get taken out in 3-4 years by one of its competitors.

BUY

Wounds (bandages), arthroscopic surgery and orthopedics. They are the largest presence in Europe, which is hurting them. A lot of people have lost their healthcare coverage and is hurting the industry. Ultimately this stock will do well.

PAST TOP PICK

(A Top Pick Nov 19/10. Down 2.76%.) Economic environment has taken some of the wind out of their sails but they'll come back.

PAST TOP PICK

(Top Pick Nov 10/10, Up 2.12%) knee replacements, demographic play. Last year and a half have not been that robust because knee replacements are a little bit elective. There is a pent up demand for this kind of surgery. Some interest in the space from some of their competitors.

TOP PICK

(London Stock exchange.) Medical devices. This sort of business that can continue to grow a respective of the economy. Good price.

TOP PICK

Medical device manufacturer for replacement hips and knees. Huge demographic area. Not particularly expensive at less than 15X earnings. Strong balance sheet. Could be a takeout candidate.

PAST TOP PICK

(A Top Pick Jan 5/10. Up 16.75%.)

PAST TOP PICK

(A Top Pick Dec 29/09. Down 7.58%.) Still a Buy.

TOP PICK

Valuation is closer to $60. Likes the demographics for hip and knee replacements. Took a bit of a dip through 2008-2009 as the economy contracted.

PAST TOP PICK

(A Top Pick June 12/09. Up 18.92%.) Still likes.

PAST TOP PICK

(A Top Pick May 8/08. Up 38.71%.)

Showing 16 to 30 of 46 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Bruce Murray

The Murray Wealth Group

Joe Terranova

Virtus Investment Partners

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Smith & Nephew PLC (SNN)